- Home
- CASI
as 05-09-2025 4:00pm EST
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
| Founded: | 1991 | Country: | China |
| Employees: | N/A | City: | N/A |
| Market Cap: | 31.0M | IPO Year: | 1996 |
| Target Price: | $4.00 | AVG Volume (30 days): | 8.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.64 - $7.67 | Next Earning Date: | 05-20-2025 |
| Revenue: | $28,537,000 | Revenue Growth: | -15.77% |
| Revenue Growth (this year): | -32.8% | Revenue Growth (next year): | N/A |
Latest CASI Pharmaceuticals Inc. News
CASI Breaking Stock News: Dive into CASI Ticker-Specific Updates for Smart Investing
ACCESS Newswire
3 days ago
CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement
ACCESS Newswire
a month ago
CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company
Simply Wall St.
a month ago
CASI Pharmaceuticals Full Year 2024 Earnings: US$2.56 loss per share (vs US$2.02 loss in FY 2023)
ACCESS Newswire
a month ago
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results
Simply Wall St.
3 months ago
This CASI Pharmaceuticals Insider Increased Their Holding By 65% Last Year
ACCESSWIRE
4 months ago
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia
Simply Wall St.
6 months ago
CASI Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
ACCESSWIRE
6 months ago
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
Compare CASI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CASI CASI Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.